The possible involvement of adenylate cyclase inhibition in the field potential suppression through alpha-2 adrenergic receptors in the bed nucleus of the stria terminalis.
Catecholamines, such as norepinephrine (NE), cause a field potential suppression through alpha-2 adrenergic receptors in thin sections of the bed nucleus of the stria terminalis. Phosphodiesterase inhibitors or cyclic AMP (cAMP) analogues attenuate the NE-induced suppression. These results suggest that the NE-induced suppression is mediated by adenylate cyclase inhibition and a resultant decrease of intracellular cAMP content.
D015056:1-Methyl-3-isobutylxanthine / Q000008:administration & dosage; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000008:administration & dosage; D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D003994:Bucladesine / Q000008:administration & dosage; D003839:Deoxyadenosines / Q000008:administration & dosage; D004027:Diencephalon / Q000187:drug effects*; D004347:Drug Interactions; D004594:Electrophysiology; D006168:Guinea Pigs; D009638:Norepinephrine / Q000494:pharmacology*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D013872:Thionucleosides / Q000008:administration & dosage
D000067956:Adenylyl Cyclase Inhibitors; D003839:Deoxyadenosines; D011942:Receptors, Adrenergic, alpha; D013872:Thionucleosides; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; C008500:5'-methylthioadenosine; D003994:Bucladesine; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine; D009638:Norepinephrine